Coronary artery disease remains to be the leading cause of morbidity and mortality in industrialized nations. Current treatments for small diameter grafts are limited by the availability of suitable autologous vessels and high thrombogenic potential of synthetic grafts. There is a clinical need to development of tissue engineered blood vessels (TEBV) suitable for vascular by pass grafting.

This content is only available via PDF.
You do not currently have access to this content.